Dust, smoke, and chemicals in the air cause about 1%-2% of lung cancers. Researchers suspect that polluted air can cause ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

TYK Medicines, Inc. Class H ( ($HK:2410) ) has provided an announcement. TYK Medicines, Inc announced positive results from its Phase II clinical ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC ...

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, with approximately 20% of patients ...

Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...